• Experimental Hematology

    Cellular aging is inextricably linked to the acquisition of DNA damage which depletes our adult stem cell reserves and directly precipitates age-related diseases including cancer. By understanding the processes via which our stem cells accumulate DNA with age, we can enhance preventative medicine by defining environmental risk factors that lead to DNA damage.
    +Read More
  • Experimental Oncology

    Individual cancer cells functionally differ from each other, even in the same patient. We study these differences to develop novel therapeutic strategies.
    +Read More
  • Metastatic Niches

    Disseminated cancer cells engage and manipulate the microenvironment at distant sites and generate a metastatic niche for their own advantage.
    +Read More
  • 1
  • 2
  • 3


HI-STEM gGmbH is a non-profit public-private partnership between the German Cancer Research Center (DKFZ) in Heidelberg and the Dietmar Hopp Stiftung.

HI-STEM performs cutting-edge research on stem cells with the aim of translating these results into novel clinical applications. This includes the development of novel diagnostic tools and innovative therapies to monitor and target leukemic and solid tumor stem cells as well as metastatic disease.

HI-STEM was founded in 2008 and is located in newly renovated laboratories and offices within the main building of the DKFZ.
The managing director of HI-STEM, Professor Dr. Andreas Trumpp and five Junior Group Leaders direct an international team of more than fifty scientists, PhD/Masters students and technical staff. Together, this forms an excellent environment to perform cutting edge translational research and to train the next generation of outstanding young scientists.

The HI-STEM Research Groups:

Researchers at HI-STEM are working in close collaboration with colleagues of the University Clinical Centers in Heidelberg, Mannheim and other cities as well as with the National Center for Tumor Diseases (NCT) in Heidelberg. In addition, HI-STEM collaborates with various biotechnology and pharmaceutical companies to investigate and develop novel strategies to push forward the development of new drugs and effective treatments for different types of cancer and to promote their clinical application.